Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-...
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
About this item
Full title
Author / Creator
Journal title
Language
English
Formats
More information
Scope and Contents
Contents
This study examines whether neoadjuvant docetaxel, cisplatin plus S-1 (DCS) therapy is superior to docetaxel, cisplatin plus 5-fluorouracil (DCF) therapy for resectable advanced esophageal squamous cell carcinoma (ESCC).INTRODUCTIONThis study examines whether neoadjuvant docetaxel, cisplatin plus S-1 (DCS) therapy is superior to docetaxel, cisplati...
Alternative Titles
Full title
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2865787980
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2865787980
Other Identifiers
ISSN
1423-0232
E-ISSN
1423-0232
DOI
10.1159/000533790
